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The impact of socioeconomic factors on outcome
and hospital costs associated with femoropopliteal
revascularization
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Charles S. Powell, MD, and Michael C. Stoner, MD, Greenville, NC
Introduction: Within the context of healthcare system reform, the cost efficacy of lower extremity revascularization
remains a timely topic. The impact of an individual patient’s socioeconomic status represents an under-studied aspect of
vascular care, especially with respect to longitudinal costs and outcomes. The purpose of this study is to examine the
relationship between socioeconomic status and clinical outcomes as well as inpatient hospital costs.
Methods: A retrospective femoropopliteal revascularization database, which included socioeconomic factors (household
income, education level, and payor status), in addition to standard demographic, clinical, anatomical, and procedural
variables were analyzed over a 3-year period. Patients were stratified by income level (low income [LI] <200% federal
poverty level [$42,400 for a household of 4], and higher income [HI]>200% federal poverty level) and revascularization
technique (open vs endovascular) and analyzed for the endpoints of primary assisted patency, amortized cost-per-day of
patency, and limb salvage. Data were analyzed with univariate and multivariate techniques.
Results: A total of 187 cases were identified with complete data for analysis, 146 in the LI and 41 in the HI cohorts. LI
patients differed from HI patients by mean age (66.2  1.0 vs 61.8  1.5 years, P  .04), high school graduate rate
(51.4% vs 85.4%, P < .001), presence of tissue loss (30.1% vs 14.6%, P  .05), female gender (43.7% vs 22.0%, P  .01)
and preoperative statin use (45.8% vs 75.6%, P < .001). There were no differences with respect to other comorbidities
including smoking status, presence of diabetes, renal insufficiency, anatomic factors or treatment modality (open vs
endovascular). Ninety-seven patients underwent endovascular revascularization. The following outcomes were noted in
the endovascular subset of LI andHI patients respectively: primary assisted patency (66% vs 71%, PNS) and 12-month
cost-per-day of patency ($166.30  77.40 vs $22.45  12.45, P  .05). Ninety-eight patients underwent open
revascularization, with the following outcomes in LI and HI patients respectively: primary assisted patency (78% vs 86%,
PNS) and 12-month cost-per-day of patency ($319.43 225.44 vs $40.47 4.63, P .07). Of the 77 patients with
critical limb ischemia, 19 underwent eventual amputation. Multivariate analysis demonstrated that income above 100%
of the federal poverty line was protective against limb loss (odds ratio 0.06, 95% confidence interval 0.01-0.51, P< .001).
Conclusion: Income level correlates with advanced presentation, advanced age, and lack of statin use. Although primary
assisted patency rate is not affected by income status, an increased cost-per-day of patency and inferior limb salvage is
found in lower income patients. ( J Vasc Surg 2010;52:600-7.)Nearly 40 million Americans currently live below the
federal poverty level, the highest number since 1960.1
Moreover, the number of Americans without health
insurance is increasing as well, currently over 46 million,
or 15.4 percent of the population. Medicaid and the
State Children’s Health Insurance Program enrollment
have also increased. These programs reached a combined
39.2 million in 2008, which covered 14.9 percent of the
nonelderly population- much higher than the 10.5 per-
cent level of 1999.2 Undoubtedly, the burden of caring
for these disadvantaged persons has contributed to place
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600health care spending at its current level of 16 percent of
the GDP with estimates that this will increase to 20% by
2016.3
In cardiovascular medicine, there is an association
between income status and suboptimal outcomes. Previ-
ous studies have shown that lower income is associated
with higher mortality and morbidity after myocardial
infarction.4,5 Progression of carotid atherosclerosis has
also been associated with lower incomes.6-8 Further-
more, studies have described an association between
income, geography, and lower extremity amputation vs
revascularization, as well as an association between rates
of amputation and hospitals in low income areas.9-11 The
association of income status and outcome following
lower extremity revascularization is ill-defined.
With this in mind, we reviewed our recently-published
experience with elective open and endovascular treatment
of femoropopliteal occlusive disease in low and high in-
come patient populations. The objectives of this study were
to determine if socioeconomic factors affected outcomes in
vascular reconstruction as well as to evaluate the impact of
these factors on the cost of care.
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Patient selection and data collection. To examine
the effects of income on these groups, a cohort of a con-
secutive series of patients undergoing lower extremity re-
vascularization was examined. The study was approved by
the University and Medical Center Institutional Review
Board of East Carolina University. From July 2003 to July
2006, all patients who had undergone open or endovascu-
lar treatments limited to the femoropopliteal arterial circu-
lation for chronic disease were identified in a retrospective
computerized database. Patients were identified using the
hospitals billing database using appropriate common pro-
cedural terminology (CPT) codes. No interventions below
the infrageniculate popliteal artery were included in this
database. The decision to use open bypass or endovascular
revascularization was based on clinical evaluation, anatom-
ical factors, and the attending surgeon’s preference. Preop-
erative, procedural, and outcome variables were collected
from the computerized patient care records. Basic demo-
graphic data were recorded, omitting patient identifying
information. The indication for revascularization was clas-
sified by the criteria of Rutherford et al, and critical limb
ischemia (CLI) was defined as Rutherford category  3.12
Tissue loss was defined as necrosis at admission.
Patient comorbidities were defined as:
● Diabetes mellitus: medical treatment of diabetes;
● Hypertension: medical treatment of hypertension;
● Hyperlipidemia: medical treatment of dyslipidemia or
total cholesterol  200 mg/dL;
● Tobacco use: recorded as both lifetime tobacco use
and current use;
● Coronary disease: medical therapy for coronary vascu-
lar disease or prior coronary revascularization;
● Renal insufficiency: serum creatinine 1.5 mg/dL;
● End stage renal disease: renal failure requiring chronic
renal replacement therapy.
Perioperative medical management was noted with re-
spect to the following agents: Aspirin, Clopidogrel (Plavix,
Sanofi-Aventis, Bridgewater, NJ), Warfarin (Coumadin,
Bristol-Myers Squibb, Princeton, NJ), and lipid lowering
therapy.
Anatomic and morphologic characteristics were ob-
tained by review of the archived images from the individual
cases. Calibrated angiography was used to determine lesion
lengths and infrapopliteal run-off was recorded. Run-off
was defined as run-off to the ankle. These data were used to
assign the target lesion with a Trans-Atlantic Inter-Society
Concensus (TASC II) classification.13
Specific data points were collected based on the type of
revascularization performed. Type of graft conduit and
target vessel was noted in open surgical cases. Endovascular
modality (ie, angioplasty, stenting, atherectomy, or cryo-
plasty) was documented for those undergoing endovascular
revascularization. Several data points that did not impact
the cost model were omitted from this manuscript for the
sake of simplicity and brevity.Socioeconomic data. Income and education data was
collected via telephone survey performed by the authors
after obtaining patient telephone numbers from hospital
records. Patients were queried regarding their total annual
household income. Patients were stratified into three in-
come levels. Higher income [HI] was defined as an income
greater than 200% of the federal poverty line ($42,400) and
lower income [LI] was defined as an income less than this
amount.14 An additional variable, very low income [VLI],
was defined as an income 100% FPL ($21,200). Stratify-
ing patients by these percentages of the FPL was consistent
with previous studies.15,16 Patients were also queried re-
garding completion of high school or equivalent and
whether or not some form of advanced degree beyond the
high school level had been obtained.
Long-term end points. Primary-assisted patency re-
lated to the initial treatment modality was the primary end
point in this study. Patency was determined by the guide-
lines of Rutherford et al and used routine physiologic
examinations in those without a palpable pulse including
duplex ultrasonography, ankle-brachial index (ABI), and
pulse volume recordings (PVR).12 Deterioration in clinical
status or hemodynamics (10% reduction in ABI) prompted
further imaging. Duplex ultrasonography was used to follow
all patients with a bypass graft and those with a stent. Balloon
angioplasty cases were followed solely with clinical and
physiological measures. A peak systolic velocity ratio
2.0 prompted further imaging in these patients. Total
follow-up time was recorded for each patient as well as the
time to failure of primary and primary-assisted patency.
We also determined cost per patient day of patency 12
months following the index procedure. Only hospital costs
were recorded. The time interval of 12 months was chosen
because the fraction of patients in each group available for
follow-up was equal at that time point. At longer intervals,
fewer of the endovascular patients were available for follow-
up, owing to the fact that an increasing number of the
endovascular cases took place in the latter half of the study.
For each individual patient, the cost model was used to
generate the cost per day of patency at 1 year.
Cost model. Using our previously developed amor-
tized cost model, cost efficacy characteristics were exam-
ined of low income and higher income patients undergoing
endovascular and open surgical revascularization.17 To de-
termine cost at any time, we maintain patency. This takes
into account the initial hospital cost and the cost of all
subsequent hospital interventions. This is then divided by
time in days to give the cost per day of patency.
When an intervention failed patency, the cost per day of
patency remained static throughout the remaining time
period of the study. Of note, total hospital costs were
accounted for at each time point. If a patient suffered a
complication or adverse event from a given procedure, the
financial burden of that event was included in the model
(costs and indirect costs associated with treatment of that
complication such as incision and drainage, debridement,
etc.). This also includes amputation as a means of caring for
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was considered a failure to maintain patency.
For the purpose of this study, total hospital cost (direct
and indirect cost) for the particular encounter was used to
calculate the amortized cost. This cost data was obtained
from hospital billing records. Both costs and charges were
available for review within patient billing records. How-
ever, in this study only in hospital costs, rather than charges,
were used. If a patient was admitted to the hospital for a
non-lower extremity problem, only those costs associated
with the appropriate diagnosis-related group (DRG) were
used. Costs associated with adverse outcomes after a par-
ticular revascularization were also included for the total
encounter cost calculation. Cost data was available for all
patient encounters in this study. If the patient underwent a
major amputation ipsilateral to the index revascularization,
this was included in the cost analysis. The specific number
and details of patient reinterventions were not reviewed as
these data were analyzed in our previous study. The cost
model accounted for direct revascularization costs, and,
therefore, cost of postoperative rehabilitation, nursing
home, or lost days of work was not included in this analysis.
Statistical analysis. The software code for the cost
model was developed using Microsoft Visual Basic and
employed a Microsoft Excel spreadsheet to input the data
and record the output of the model (Microsoft Corp.,
Redmond, Wash). A developmental version of this software
code is freely available under the terms of the GNU General
Public License.18 The average amortized cost per day of
patency was compared between low income and high-
income groups. Results were analyzed using the Student t
test and are presented as mean standard error. A P .05
was considered significant for all statistical analyses. Kaplan-
Meier life tables were created and patency was examined
using log-rank analysis. Multivariate Cox proportional haz-
ards model was used to analyze the categorical variables
associated with limb loss in patients with critical limb
ischemia. Variables with P  .1 as well as those that were
clinically significant in our prior femoropopliteal publica-
tions were included in the multivariate model. These data
were analyzed using SAS 9.1 software (SAS institute Inc,
Cary, NC).
RESULTS
During the study period, 432 patients were treated for
femoropopliteal disease and 187 patients completed the
telephone survey. One-hundred and forty-six of these pa-
tients had incomes that were less than 200% of the federal
poverty level [FPL] for a household of four ($42,400;
lower income [LI]). Within the lower income group, 101
patients were noted to have income, which was also less
than 100% of the FPL (very low income [VLI]). Forty-one
patients had income that exceeded 200% of the FPL
(higher income [HI]). Patient groups were well matched
with no significant differences in the following clinical
variables: race, lack of health insurance, coronary disease,
congestive heart failure, diabetes, hypertension, end stage
renal disease necessitating dialysis, preoperative creatininevalue 1.5, and tobacco use. Preoperative medical treat-
ment occurring at least 30 days prior to revascularization
showed no significant differences between groups with
regards to ASA, Plavix, or Coumadin use. There was no
significant difference in the number of patients with runoff
less than two vessels, those having femoropopliteal TASC C
or D lesions, or those with lesions greater than 10 cm.
Significant differences were seen between the two groups
with the lower income cohort being older, consisting of a
larger number of females, having a lower high school
graduation rate (or equivalent), and having lower preoper-
ative statin use. The lower income group had a higher rate
of critical limb ischemia as an indication than the higher
income group, who had a higher rate of claudication. The
lower income group also had a higher rate of tissue loss
(Table I).
Ninety-eight patients underwent endovascular repair,
and 89 patients underwent open surgical bypass. There was
no difference in treatment modality used between income
groups. Of the patients undergoing open bypass, there was
no difference in prosthetic graft use, although there was a
higher incidence of an above-the-knee popliteal distal tar-
get in the higher income cohort. Among patients undergo-
ing endovascular revascularization there were similar rates
of stent placement in addition to balloon angioplasty (Ta-
Table I. Characteristics of 187 patients undergoing
femoropopliteal revascularization stratified by income
LI (n146) HI (n  41) P value
Demographic
Age (y) 66.2  1.0 61.8  1.5* .04
Female 43.7% 22%* .01
Non-causasian 41.8% 36.6% .55
High school graduate 51.4% 85.4%** .001
Self-payor status 2.7% 0.0% .28
Comorbidities
CAD 54.1% 56.1% .82
CHF 24.1% 17.1% .35
Diabetes 48.0% 36.6% .20
HTN 88.4% 82.9% .36
ESRD 6.2% 7.3% .79
Creatinine  1.5 mg/dL 16.4% 12.2% .51
Smoking history 52.1% 55.3% .73
Preoperative medication
Statin 45.9% 75.6%** .001
ASA 73.6% 81.6% .31
Plavix 56.9% 65.8% .32
Coumadin 10.4% 5.3% .33
Anatomical
Runoff  2 vessels 49.3% 36.6% .15
TASC C or D 20.6% 19.5% .88
Lesion  10 cm 21.2% 24.4% .67
Indication
Claudication 54.1% 75.6%** .01
Critical limb ischemia 45.9% 24.4%** .01
Tissue loss 30.1% 14.6%* .05
CAD, Coronary artery disease; CHF, congestive heart failure; Cr, creatinine;
ESRD, end stage renal disease; HTN, hypertension; TASC, The Inter-
Society Consensus II femoropopliteal grade.
*P  .05, **P  .01.ble II).
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rate of primary patency failure was higher in the lower
income cohort, but did not reach statistical significance.
The 12-month primary assisted patency rates were not
significantly different in the 98 patients treated by endovas-
cular intervention (71 5% LI, 66 10% HI, PNS; Fig
1). Open primary assisted patency in this subset of patients
was also similar between the two income groups (78  5%
LI, 86  9% HI, P  NS; Fig 2). The mean number of
follow-up days was not different between groups (625.5
29.8 LI, 560.7  52.0 HI). Likewise, the two income
groups had a similar rate of follow-up at one year (74.0%
LI, 75.6% HI; Table III).
There were no differences in initial cost of endovascular
therapy (LI $6297.30 355.23, HI $6049.40 833.01)
or open procedures (LI $11985  619.92, HI $12155 
Table II. Procedural and anatomic variables of 187
patients undergoing femoropopliteal revascularization
stratified by income
LI HI P value
Open (n  89) 49.3% 41.5% .37
AK popliteal target 84.6% 100%* .01
Prosthetic graft 87.5% 88.2% .93
Runoff  2 vessels 43.1% 53.0% .46
Endovascular (n  98)
Stent placement 20.3% 20.8% .95
Runoff  2 vessels 55.4% 25.0%** .01
TASC C or D 40.5% 33.3% .53
Lesion  10 cm 41.9% 41.7% .98
CAD, Coronary artery disease; CHF, congestive heart failure; Cr, creatinine;
ESRD, end stage renal disease; HTN, hypertension; TASC, The Inter-
Society Consensus II femoropopliteal grade.
*P  .05, **P  .01.
Fig. 1. Kaplan-Meier curve for primary assisted patency in endo-
vascular subset of patients, stratified by income (12 month: LI
[blue]  71  5%, HI [green]  66  10%; P  NS).608.11). Using the aforementioned cost model, the 12-month cost per day of patency in endovascular LI group
was $166.30  77.40, compared with the HI group,
$22.45  12.45 (P  .05). The 12-month cost per day of
patency in the open LI group was $319.43  225.44
compared with $40.47  4.63 in the high income group
(P  .07; Table III).
To examine a possible confounding effect of indication,
we also analyzed the primary outcomes after further strati-
fying by claudication and critical limb ischemia. Among
patients with claudication, the 12-month primary assisted
patency in the open cohort was 91% in the LI group and
90% in the HI group (P .58). In the endovascular cohort
primary assisted patency was 79% in the LI group and 66%
in the HI group (P  .20). The 12-month cost per day of
patency in the open cohort was $508.78  475.24 in the
LI group and $42.77  6.77 in the HI group (P  0.34).
In the endovascular cohort the cost per day of patency was
$146.58 96.58 in the LI group and $20.12 3.60 in the
HI group (P  .35). This compares with the patients who
presented with critical limb ischemia. The 12-month pri-
mary assisted patency in the open cohort was 66% in the LI
group and 80% in the HI group (P .18). In the endovas-
cular cohort primary assisted patency was 59% in the LI
group and 50% in the HI group (P 0.88). The 12-month
cost per day of patency in the open cohort was $149.67 
52.43 in the LI group and $36.805.32 in the HI group
(P  .39). In the endovascular cohort the cost per day of
patency was $206.90132.13 in the LI group and $43.44
27.36 in the HI group (P  .68).Of the seventy-seven
patients with critical limb ischemia studied, 19 eventually
underwent major amputation (above-knee amputation or
below-knee amputation). All 19 cases were in the LI cohort
of patients, giving this cohort a 74% limb salvage rate at 12
months, significantly lower than the 100% salvage rate
Fig. 2. Kaplan-Meier curve for primary assisted patency in open
subset of patients, stratified by income (12 month: LI [blue] 
78  5%, HI [green]  86  9%; P  NS).among higher income patients (Fig 3). A Cox Hazard
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100% of the FPL (very low income [VLI]); a higher income
was uniquely protective against limb loss (Table IV).
DISCUSSION
Individual economic status has been shown to be a
barrier to adequate care. Whether it is primary care of
diabetes, mammogram rates, or rates of admission to a
cardiac care unit after a myocardial infarction, the poor are
at a disadvantage to accessing care compared with those of
a higher socioeconomic status.9,19,20 This has manifest
itself in the poor using the emergency department at higher
rates, likely substituting the emergency department for the
advantage of the continuity of primary care physician and
thus further impacting their medical needs.21 Germaine to
the practice of vascular surgery, lower socioeconomic status
has been shown to correlate with a higher rate of peripheral
artery disease.22 Because income status has also been shown
Table III. Outcomes of 187 patients undergoing femoro
Failure 3
12-month assisted patency
Endovascular 7
Open 7
12-month follow-up 7
Initial Cost ($)
Endovascular 6297.3
Open 1198
12-month amortized cost ($/patient-day)
Endovascular 166.3
Open 319.4
Failure, Failure of index revascularization.
*P  .05.
Fig 3. Kaplan-Meier curve for limb salvage in patients with criti-
cal limb ischemia stratified by income (12 month: LI [blue] 74
6%, HI [green]  100  0%, P  .01).to correlate with poor outcomes in other aspects of cardio-vascular disease, it is necessary to understand how income
affects outcomes in patients with peripheral artery dis-
ease.23 Race has also been shown to correlate with sub-
optimal outcomes in patients with peripheral arterial dis-
ease.24 In the current study, race was not a significant
variable when comparing low and high-income groups,
likely a consequence of the overall socioeconomic makeup
of our rural underserved referral pattern.
The purpose of this study was to evaluate the outcomes
of different income subsets of patients undergoing femoro-
popliteal revascularization. As written documentation of
income status and education level was not available in
hospital records, it was necessary to contact the patients via
telephone survey. The decision to use 200% of the FPL as
the point by which to stratify patients was based on previous
studies and accepted standards in the literature, although
using a different multiple of the FPL could produce differ-
ing results.15,16,21
The groups were well matched. The lower rate of high
school graduation in the lower income group is not surpris-
ing, as it may be intuitive that education and income are
teal revascularization stratified by income
HI P value
22.1% .19
66% .25
86% .81
75.6% .83
55.23 6049.40  833.01 .75
19.92 12155  608.11 .90
7.40 22.25  12.45* .05
25.44 40.47  4.63 .07
Table IV. Cox-Hazard ratios for variables correlated
with limb salvage in patients with critical limb ischemia
Odds
ratio
95% Confidence
limits P value
Clinical
Age  80 years 4.446 0.752-26.280 .099
Diabetes 1.187 0.385-3.661 .765
Preoperative statin 0.660 0.193-2.254 .508
Lack of statin therapy 0.708 0.066-7.591 .776
Smoking history 2.542 0.627-10.298 .191
Anatomical
 2 vessel runoff 1.144 0.367-3.565 .816
TASC C or D lesion 0.216 0.023-2.009 .178
Tissue loss 2.965 0.989-8.889 .052
Socioeconomic
Income  100% FPL 0.057 0.006-0.502 .01
High school degree 1.628 0.532-4.983 .394
Self-pay status 0.001 0.001-999.999 .985
*P  .05; P  .01.popli
LI
0.7%
1%
8%
4.0%
0  3
5  6
0  7
3  2correlated, although there are many exceptions to this
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ative medical management were similar with the only ex-
ception being an increased use of a statin in the higher
income group. As statin use has already been shown to
improve symptoms and outcomes in peripheral artery dis-
ease, this is an important distinction and further highlights
the barriers to care that the poor experience.25, 26 Anatomic
variables of disease such as lesion length and TASC classi-
fication were similar although the indication for therapy
was different between income cohorts. The rate of pros-
thetic graft use in the open cohorts, while not different
between income groups, is high secondary to the strategy
employed by the authors. Often, serial revascularizations
are necessary in this patient population, and natural vein
grafts are reserved for those who have initially failed bypass
with prosthetics. The lower income group had higher rates
of critical limb ischemia and tissue loss upon presentation
than the higher income group, which was more frequently
intervened upon for claudication. In this study, poverty is a
marker for more advanced peripheral artery disease, al-
though it is unclear if this is secondary to lack of access to
care, intrinsic health issues, or lack of education. This associa-
tion has previously been described in the literature.27
The primary assisted-patency rates in both endovascu-
lar and open subsets of both income cohorts were lower
than might be expected in other geographical areas. How-
ever, in this patient population, a large number of patients
have never been medically treated for their vascular disease,
or there is a lack of adherence to best medical practices by
providers who have evaluated these patients. The lower
than expected preoperative statin and antiplatelet therapy
rates in both income cohorts is a manifestation of this.
There was no significant difference in primary-assisted pa-
tency between income groups in either the endovascular or
open subset, but the cost per day of patency at 12 months
in the lower income group was greater than those with a
higher income in the endovascular subset, and there is a
trend toward such an association in the open group as well.
This greater cost, despite similar assisted-patency rates, is
secondary to the higher rate of primary patency failure seen
in the LI group. Many of these failures in the endovascular
cohort of LI patients were noted to be early in the postop-
erative course. Considering the additional costs associated
with subsequent procedures, these early failures of patency
weigh heavily on our amortized cost model, and as a result,
durability becomes the principle driving force in this cost-
efficacy framework. In our previous studies, the strongest
predictor of an early revascularization failure was chronic
renal failure.16
Multivariate analysis revealed that among patients with
critical limb ischemia, an income greater than 100% of the
FPL was protective against limb loss after lower extremity
revascularization. The reasons for this are likely multifacto-
rial. It has been shown that lower socioeconomic status is
associated with a lesser amount of time devoted to exercise
as well as higher levels of vascular inflammatory mark-
ers.13,28 This could contribute to the lower likelihood of
success of revascularization in patients with critical limbischemia in the lower income subset. The number of visits
to a primary care physician has been shown to correlate with
amputation outcome as has a lack of outpatient education
for comorbid conditions.29,30 Patients with lower income
may have more barriers to accessing adequate care, and
therefore miss an opportunity for early diagnosis and treat-
ment of arterial occlusive disease.31 Although there were no
comorbid differences seen between income groups, how or
to what level of success these conditions were being man-
aged was not assessed. Moreover, those patients in the
lower income group were significantly older than the
higher income group, suggesting a possible delay in their
initial presentation to either a primary care physician or a
vascular surgeon, as has been previously suggested.31 In
any case this is an area deserving further exploration.
Within the current context of healthcare reform, this
study highlights some important aspects of indigent care.
Removing the aforementioned barriers to care could pro-
vide the economically disadvantaged with adequate pri-
mary care prior to the development of peripheral artery
disease, perhaps lessening the gap between those with less
and those who are more affluent. As this study shows, this
may not only produce better results for the individual
patient, but may reduce the burden of their care on the
healthcare system as a whole.
The retrospective nature of the database as well as the
treatment biases that exist from reviewing the records of
only a single institution are noted limitations. Furthermore,
the socioeconomic data were collected via telephone survey
and were not verified by official means such as tax returns or
school records. The assumption was made that subjects
were aware of and accurate in reporting these data. Another
limitation of this study is the lack of a sensitivity analysis
considering the cost elements that were not included.
Finally, the relatively small group of patients on which the
conclusions from this analysis are based subjects the study
to the potential for significant statistical error.
CONCLUSION
In patients undergoing femoropopliteal revasculariza-
tion, income level correlates with advanced disease state
presentation, advanced age (possibly a proxy for delayed
presentation) and lack of statin use. While the primary
assisted patency rate is not affected by income status in this
study, lower income patients demonstrate an increased
cost-per-day of patency and inferior limb salvage compared
with higher income patients. These data establish a rela-
tionship between income and metrics of lower extremity
revascularization success, and demonstrate the financial and
clinical burden associated with caring for these patients.
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Dr Julie A. Freischlag (Baltimore, Md). This retrospective
analysis of the impact of one’s socioeconomic status on the cost
and outcomes of lower extremity bypass as with most provoca-
tive studies raises more questions than it answers. It also does
not include a non-operative and/or exercise group which I
believe would have the lowest cost-per-day as one of its many
advantages.
This is a small (187 cases) retrospective study- how can you be
sure that your findings do not reflect a type 2 error- and perhaps
with a larger prospective data base the answer could show equiva-
lence between groups? Household income and education level
were also self-reported and could be exaggerated. Follow-up was
only 12 months for patency and cost-per-day, which is very limitedmay have been seen in the endovascular group. Cost was only
assessed for those costs accrued in hospital- outpatient expenses
and lost days of work were not included. Therefore this is really a
snapshot of the cost of hospitalization. The primary assisted pa-
tency rates were not different between the groups- but were low in
both groups- can you explain what kinds of procedures were
needed to achieve the primary assisted rates and why were they
low?
This paper is one of the first in our vascular literature to
address the cost of intervention and I applaud the authors for their
attempt.
Dr Durham (Greenville, NC). Thank you for your questions
and comments. Without question, the primary weakness of the
study is its nature as a small retrospective database, so yes, there is
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 3 Durham et al 607a possibility of a type II error. As you mentioned, another potential
flaw of the study is the reliability of patients to accurately report
income and education data. I do not think we would have been
able to confirm this information via submission of diplomas or tax
returns. When calling these patients on the phone, some of them
were very hesitant to talk about their incomes, and to ask them to
present more reliable means of reporting those things might have
been difficult. The decision to report patency and cost-per-day of
patency at 12-months was based on the divergence of follow-up
between the groups past 12 months. With regard to this being a
snapshot of hospital costs, I agree that a more extensive assessment
of outpatient expenses such as those associated with rehabilitation
and societal costs such as days away from work is warranted. At ourinstitution, we are building a prospective database of all patients
that come through our department. A more comprehensive assess-
ment of costs, rather than just hospital costs, will be included as
well as income and education data. They are not statistically
different, but primary assisted patency rates of 60% to 70% in both
the lower and higher income groups are lower than what one
would expect. This is reflective of our patient population. For
instance, the number of patients who are on preoperative statin
therapy in the higher income group was only 76%. For these
patients, this should approach 100%. Moreover, the aspirin level
even for the higher income cohort was only 81%. This should be
higher as well. These examples illustrate the poor access to care in
our rural underserved region.
